Septerna (SEPN) Long-Term Investments (2024 - 2026)
Septerna's quarterly Long-Term Investments came in at $174.7 million in Q1 2026, up 180.66% year-on-year from $62.2 million in Q1 2025, and up 10.87% quarter-over-quarter from $157.6 million in Q4 2025.
Septerna has reported Long-Term Investments for 3 years, with the latest figure at $174.7 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments rose 180.66% year-over-year to $174.7 million; the trailing twelve-month figure through Mar 2026 stood at $174.7 million (up 180.66% YoY), and the FY2025 full-year result was $157.6 million, up 125.53% from the prior year.
- Long-Term Investments for Q1 2026 stood at $174.7 million, up from $157.6 million in the prior quarter.
- The five-year high for Long-Term Investments was $174.7 million in Q1 2026, with the low at $7.0 million in Q3 2024.
- Average Long-Term Investments over 3 years is $87.3 million, with a median of $69.9 million recorded in 2024.
- Peak annual rise in Long-Term Investments reached 1149.63% in 2025, while the deepest fall reached 125.53% in 2025.
- Tracing SEPN's Long-Term Investments over 3 years: stood at $69.9 million in 2024, then soared by 125.53% to $157.6 million in 2025, then advanced by 10.87% to $174.7 million in 2026.
- The last three Long-Term Investments figures came in at $174.7 million (Q1 2026), $157.6 million (Q4 2025), and $87.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 174.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 174.69 Mn |
| Dec 31, 2025 | 157.57 Mn |
| Sep 30, 2025 | 87.21 Mn |
| Jun 30, 2025 | 52.63 Mn |
| Mar 31, 2025 | 62.24 Mn |
| Dec 31, 2024 | 69.87 Mn |
| Sep 30, 2024 | 6.98 Mn |